Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025

Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDaniel MunárrizEPEstefanía PérezCMCarlos Martín‐Rodríguez

Discussion

Loading...

Member takes

Overview

Analysis reveals donor age ≥30 years worsens overall survival and non-relapse mortality in acute myeloid leukemia patients, suggesting younger donors enhance outcomes.

Key Points

  • Young donors (<30 years) significantly reduce rates of aGVHD, with only 3.0% experiencing grade II–IV versus 19.9% from older donors.
  • Overall survival is better with younger donors, showing 80.6% at two years compared to 64.3% for those ≥30 years.
  • Donor age ≥30 years is an independent predictor of inferior outcomes, with an HR of 1.88 for overall survival.
  • Prioritizing younger donors can improve transplant outcomes in patients with acute myeloid leukemia.

Cite This Study

Munárriz et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0df9https://doi.org/10.21203/rs.3.rs-7169285/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC2025 · 1 citations
  2. 2Older donor age is not associated with inferior survival in contemporary haploidentical transplantation2025
  3. 3Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  4. 4Donor‐Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single‐Center Retrospective Cohort Study of a Modified Combination of Anti‐Thymocyte Globulin and Post‐Transplant Cyclophosphamide2026
  5. 5Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia2025